NIHSAD to be upgraded to BSL-4 lab for testing deadly pathogens
Bhopal: The ICAR-National Institute of High Security Animal Diseases (NIHSAD) in Bhopal will upgrade its facilities to Biosafety Level-4 (BSL-4), the highest level of biocontainment, to bolster the country's preparedness against deadly pathogens such as
Nipah virus
, Crimean-Congo haemorrhagic fever (CCHF), and novel arenaviruses.
The announcement was made by institute director Dr Aniket Sanyal during NIHSAD's 25th foundation day celebrations on Monday.
The laboratory has processed over 13 lakh samples from domestic livestock and poultry. The upgrade to BSL-4 status will require significant infrastructure improvements to ensure safe handling of extremely dangerous and exotic pathogens, particularly those that pose severe risks to humans and animals and lack available vaccines or treatments.
Currently operating at BSL-3+ level, NIHSAD handles serious zoonotic diseases including avian influenza and African swine fever. The proposed BSL-4 status represents the highest level of biosafety protocols, necessary for managing lethal threats such as Nipah virus, CCHF, and novel arenaviruses.
Dr B Patnaik, who established the National Institute of Food & Mouth Diseases (NIFMD) BSL-4 Laboratory in Bhubaneswar and serves as a Biosafety Expert, delivered insights on the technical considerations and forthcoming challenges in diagnosing Exotic diseases within BSL-4 facilities.
Situated on the outskirts of Bhopal, the institute has served as a crucial facility for safeguarding animal and human health across India for 25 years, operating behind sophisticated biosafety barriers and advanced equipment.
During the 25th foundation day celebration, Dr Sanyal presented the institute's scientific achievements. Chief guest Prof (Dr) Col AK Gahlot, former Vice Chancellor of RAJUVAS, Bikaner, stressed the importance of establishing a BSL-4 laboratory, considering global disease developments.
Dr SC Dubey, former joint director of HSADL, IVRI, delivered the silver jubilee address at the event.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
18 minutes ago
- News18
Indias Shubhanshu Shuklas Axiom-4 mission now targeting June 25 launch
Agency: PTI Last Updated: New Delhi, Jun 24 (PTI) Indian astronaut Shubhanshu Shukla's Axiom-4 mission to the International Space Station is now eyeing a launch on June 25, NASA announced on Tuesday. The Axiom-4 mission, which marks the return to space for India, Hungary, and Poland, was earlier scheduled for lift-off from NASA's Kennedy Space Centre in Florida on June 25 onboard SpaceX's Falcon 9 rocket at 12:01 pm IST on Wednesday. 'NASA, Axiom Space, and SpaceX are targeting 2:31 a.m. EDT (12:01 IST), Wednesday, June 25, for launch of the fourth private astronaut mission to the International Space Station, Axiom Mission 4," a NASA statement said. The Axiom-4 commercial mission is led by Commander Peggy Whitson, with Shukla as mission pilot and Hungarian astronaut Tibor Kapu and Poland's Slawosz Uznanski-Wisniewski as mission specialists. The mission was originally scheduled for lift-off on May 29 but was then put off to June 8, then June 10 and June 11, when engineers detected a liquid oxygen leak in the boosters of the Falcon-9 rocket and NASA also detected leaks in the ageing Russian module of the International Space Station. The launch was then planned for June 19 and then on June 22 which was put off to allow NASA evaluate operations of the ISS after repairs in the Russian module. The mission will lift off from Launch Complex 39A at NASA's Kennedy Space Centre in Florida. The targeted docking time is approximately 7 am (4:30 pm IST) Thursday, June 26, NASA said. PTI SKU SCY First Published: June 24, 2025, 06:45 IST
Time of India
7 hours ago
- Time of India
NIHSAD to be upgraded to BSL-4 lab for testing deadly pathogens
Bhopal: The ICAR-National Institute of High Security Animal Diseases (NIHSAD) in Bhopal will upgrade its facilities to Biosafety Level-4 (BSL-4), the highest level of biocontainment, to bolster the country's preparedness against deadly pathogens such as Nipah virus , Crimean-Congo haemorrhagic fever (CCHF), and novel arenaviruses. The announcement was made by institute director Dr Aniket Sanyal during NIHSAD's 25th foundation day celebrations on Monday. The laboratory has processed over 13 lakh samples from domestic livestock and poultry. The upgrade to BSL-4 status will require significant infrastructure improvements to ensure safe handling of extremely dangerous and exotic pathogens, particularly those that pose severe risks to humans and animals and lack available vaccines or treatments. Currently operating at BSL-3+ level, NIHSAD handles serious zoonotic diseases including avian influenza and African swine fever. The proposed BSL-4 status represents the highest level of biosafety protocols, necessary for managing lethal threats such as Nipah virus, CCHF, and novel arenaviruses. Dr B Patnaik, who established the National Institute of Food & Mouth Diseases (NIFMD) BSL-4 Laboratory in Bhubaneswar and serves as a Biosafety Expert, delivered insights on the technical considerations and forthcoming challenges in diagnosing Exotic diseases within BSL-4 facilities. Situated on the outskirts of Bhopal, the institute has served as a crucial facility for safeguarding animal and human health across India for 25 years, operating behind sophisticated biosafety barriers and advanced equipment. During the 25th foundation day celebration, Dr Sanyal presented the institute's scientific achievements. Chief guest Prof (Dr) Col AK Gahlot, former Vice Chancellor of RAJUVAS, Bikaner, stressed the importance of establishing a BSL-4 laboratory, considering global disease developments. Dr SC Dubey, former joint director of HSADL, IVRI, delivered the silver jubilee address at the event.
&w=3840&q=100)
Business Standard
10 hours ago
- Business Standard
Eli Lilly's weekly insulin efsitora shows positive results in Phase 3
US-based pharmaceutical company Eli Lilly on Monday announced findings from the Phase 3 clinical trials for its once-weekly investigational insulin drug, efsitora alfa (efsitora), indicating positive safety and efficacy results for A1C reduction compared to daily basal insulin. While basal insulin is a long-acting insulin administered once or twice a day, efsitora is designed for once-weekly subcutaneous injection. The company also shared detailed results from the Phase 3 QWINT-1, QWINT-3 and QWINT-4 trials. The QWINT-1 trial evaluated adults initiating insulin therapy, while QWINT-3 assessed individuals previously using daily basal insulin. QWINT-4 included participants using both basal and mealtime insulin. 'In each study, efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin,' the company stated. According to Lilly, in QWINT-1, efsitora reduced A1C by 1.31 per cent compared to 1.27 per cent for insulin glargine at week 52 for the efficacy estimand. In QWINT-3, the drug reduced A1C by 0.86 per cent compared to 0.75 per cent for insulin degludec at week 26. 'In QWINT-4, efsitora reduced A1C by 1.07 per cent, matching insulin glargine's reduction of 1.07 per cent at week 26 for the efficacy estimand,' Lilly added. The Phase 3 global clinical development programme for the diabetes drug began in 2022 and included over 3,000 participants with type 2 diabetes across four global registration studies. Commenting on the results, Jeff Emmick, senior vice president of product development at Lilly, said that the once-weekly insulin therapy may offer a significant advancement for people with type 2 diabetes who need insulin, by eliminating over 300 injections a year. The company added that the drug also has the potential to provide more stable glucose levels—reducing glucose variability—throughout the week. Eli Lilly now plans to submit the drug to global regulatory agencies for the treatment of type 2 diabetes in adults by the end of 2026.
